Literature DB >> 15270428

Dysphonia and laryngopharyngeal reflux.

U Cesari1, J Galli, F Ricciardiello, M Cavaliere, V Galli.   

Abstract

The correlation between laryngo-pharyngeal reflux and dysphonia has been evaluated in patients without significant laryngoscopic findings and without vocal misuse. Studies were performed, using a validated questionnaire on typical reflux symptoms as well as instrumental means, e.g. videolaryngoscopy, multi-electrode 24-hr oesophageal pH monitoring, vocal acoustic analysis, gastro-oesophagoscopy, on 62 patients (51 male, 11 female) with dysphonia for > or = 3 months, selected from 350) consecutive patients presenting with voice disorders. Standard criteria were: absence of laryngeal neoformation (benign or malignant) and correct use of voice. Anti-reflux treatment was prescribed in all selected patients. A group of 62 selected patients without laryngo-pharyngeal disease were studied as controls. Mean values of the harmonic to noise ratio and maximum phonation time were pathological in all patients with dysphonia and significantly correlated (p = 0) with the entity of the larynx alteration. The 24-hour pH monitoring revealed gastro-oesophageal reflux in all cases with a clear prevalence of episodes in the upright, compared to supine, position. From a multiple regression analysis of pH-metric values, considered important in predicting maximum phonation time and harmonic to noise ratio alteration. the significant predictors (p < 0.01) were those parameters indicating the existence of a laryngo-pharyngeal reflux disease: in an upright position, the prevalence of the number of refluxes and of time of pH < 4. In conclusion, the association between electro-acoustic reliefs and laryngoscopic data, as well as an alteration in maximum phonation time and harmonic to noise ratio in patients with pH-metric indicative parameters of laryngo-pharyngeal reflux disease led to the hypothesis of a possible correlation between entity and duration of the reflux and dysfunction of the arytenoid muscles, upon which chronic vocal fatigue, with consequent laryngeal compensatory stress, depends.

Entities:  

Mesh:

Year:  2004        PMID: 15270428

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  6 in total

1.  How uncomplicated total thyroidectomy could aggravate the laryngopharyngeal reflux disease?

Authors:  Alessia Cusimano; I Macaione; E Fiorentino
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-09       Impact factor: 2.503

2.  A Comprehensive Voice Analysis in Benign Vocal Fold Lesions Treated by Cold Knife Endolaryngeal Surgery Using Subjective, Objective and Video-Stroboscopic Parameters.

Authors:  Anshu Singh; Aparaajita Upadhyay; Anubhav Shrivastava; R K Mundra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-03-30

Review 3.  Voice outcomes of laryngopharyngeal reflux treatment: a systematic review of 1483 patients.

Authors:  Jérôme R Lechien; Camille Finck; Pedro Costa de Araujo; Kathy Huet; Véronique Delvaux; Myriam Piccaluga; Bernard Harmegnies; Sven Saussez
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-23       Impact factor: 2.503

4.  Role of PH Monitoring in Laryngopharyngeal Reflux Patients with Voice Disorders.

Authors:  Swati Maldhure; Ramanathan Chandrasekharan; Amit-Kumar Dutta; Ashok Chacko; Mary Kurien
Journal:  Iran J Otorhinolaryngol       Date:  2016-11

5.  Laryngopharyngeal reflux disease, prevalence and clinical characteristics in ENT department of a tertiary hospital Tanzania.

Authors:  Willybroad A Massawe; Aslam Nkya; Zefania Saitabau Abraham; Kassim M Babu; Ndeserua Moshi; Aveline A Kahinga; Daudi Ntunaguzi; Enica R Massawe
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-08-26

6.  Effects of omeprazole over voice quality in muscle tension dysphonia patients with laryngopharyngeal reflux.

Authors:  Tolga Kandogan; Gökce Aksoy; Abdullah Dalgic
Journal:  Iran Red Crescent Med J       Date:  2012-12-06       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.